Document Detail


Vascular protection with cilazapril in hypertension.
MedLine Citation:
PMID:  1381792     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Anatomical changes of arteries and arterioles secondary to hypertension explain most of the late complications of this disease. Therefore, a series of experiments was performed to characterize the vascular protective effects of cilazapril in experimental hypertension. These experiments aimed to answer three types of questions: (a) In which vascular bed is cilazapril effective? (b) Are the vascular changes induced by cilazapril associated with functional effects? (c) Is the effect of cilazapril only preventive or can cilazapril also be effective when hypertension is already present? Our results show that cilazapril is acting on nearly every vascular bed. Its vascular morphological effects (decrease of vascular hypertrophy) are associated with functional changes such as improvements of coronary or cerebral vascular reserves. Cilazapril is active either as a preventive treatment or given when hypertension is already present.
Authors:
J P Clozel; H Kuhn; F Hefti
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Journal of cardiovascular pharmacology     Volume:  19 Suppl 5     ISSN:  0160-2446     ISO Abbreviation:  J. Cardiovasc. Pharmacol.     Publication Date:  1992  
Date Detail:
Created Date:  1992-10-15     Completed Date:  1992-10-15     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  7902492     Medline TA:  J Cardiovasc Pharmacol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  S28-33     Citation Subset:  IM    
Affiliation:
Pharma Division, Preclinical Research, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiotensin-Converting Enzyme Inhibitors / pharmacology*,  therapeutic use
Animals
Arteries / drug effects*,  ultrastructure
Arterioles / drug effects*,  ultrastructure
Cilazapril
Disease Models, Animal
Hypertension / drug therapy*,  pathology,  prevention & control
Pyridazines / pharmacology*,  therapeutic use
Rats
Rats, Inbred SHR
Regional Blood Flow / drug effects
Vascular Resistance / drug effects
Chemical
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 0/Pyridazines; 92077-78-6/Cilazapril

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Role of angiotensin-converting enzyme inhibitors in preventing or reducing end-organ damage in hyper...
Next Document:  Endothelium-dependent regulation of resistance arteries: alterations with aging and hypertension.